Tenderwize
Retour à la recherche

Non-exclusive pharmaceutical rebate agreement for Glatiramer acetate PEN

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jun 30, 2027 · 306 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. AM-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Glatirameracetat in der Darreichungsform PEN (ATC-Code nach WHO: L03AX13)

20/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

20 / 100

Complexité

30 / 100

Facteurs de risque

The demanded quantity is unknown and not guaranteed. It depends on patient numbers, prescription behavior, and pharmacy...

AOK PLUS reserves the right to terminate the open-house model prematurely if exclusive agreements are made (typically w...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Supply of Glatiramer acetate in PEN dosage form (ATC L03AX13) to patients insured by AOK PLUS in Saxony and Thuringia
  • Non-exclusive rebate agreement; no guaranteed purchase volumes or exclusivity
Afficher le résumé complet

Non-exclusive pharmaceutical rebate agreement (Rabattvereinbarung) under §130a Abs.8 SGB V via an open-house model for Glatiramer acetate in PEN dosage form (ATC L03AX13), managed by AOK PLUS for Saxony and Thuringia. Open to all qualified pharmaceutical entrepreneurs; no exclusivity, no guaranteed volumes, and no traditional award criteria. The contract ends 30.06.2027. First submission deadline: 02.06.2025; further rolling deadlines available. Detailed terms and discount amounts are confidential and available only after access to the DTVP project room. This publication is for transparency only and not a formal procurement procedure.

Risques

The demanded quantity is unknown and not guaranteed. It depends on patient numbers, prescription behavior, and pharmacy...

AOK PLUS reserves the right to terminate the open-house model prematurely if exclusive agreements are made (typically w...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs.18 AMG with respect to the offered medicinal products
  • Must accept the fixed terms of the rebate agreement; no individual negotiations

Eligibility

  • Must submit a declaration of no grounds for exclusion (§§123,124 GWB) and a declaration regarding Russia sanctions (EU Reg. 833/2014)

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria applied; participation is open to all qualified entrepreneurs who accept the terms.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive pharmaceutical rebate agreement for Glatiramer acetate PEN

Non-exclusive rebate agreement for the supply of Glatiramer acetate in PEN formulation to AOK PLUS for patients in Saxony and Thuringia. Open-house model; no minimum volume guaranteed; no exclusivity; contract ends 30.06.2027.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jun 2025 - Jun 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria applied; participation is open to all qualified entrepreneurs who accept the terms.

Date limite

Expired Jun 02, 2025

Détails de la procédure

Date de publication
17 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
255277-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30